Heartcore Capital

Templafy ApS, established in 2013, specializes in template and document management solutions. Its core product, the Templafy platform, connects and manages an organization's entire document ecosystem. Key features include template and content accessibility, dynamic personalization, document automation, brand and content validation, template governance, and PowerPoint productivity services. Templafy serves a wide range of industries, including banking, consulting, education, insurance, and legal, with a global presence across North America, Europe, Asia, and Australia. The company's innovative platform automates business document creation, ensuring brand compliance, governance, and improved productivity. It supports over 800 enterprise customers worldwide, such as KPMG and IKEA, and has raised $200 million in funding from prominent investors.

Grandhood is an investment management company based in Copenhagen, Denmark, founded in 2016. It specializes in providing innovative retirement planning and pension services through a digital self-service platform. The company aims to modernize the workplace pension industry by offering a user-friendly application that enables employers to facilitate access to pensions for their employees. In addition to retirement solutions, Grandhood's offerings include voluntary health insurance and insurance coverage for reduced working capacity, death, and certain critical illnesses. The company is committed to delivering low-cost, efficient advisory services, with a focus on rapid customer support and ongoing product innovation to meet the evolving needs of its clients.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Templafy ApS, established in 2013, specializes in template and document management solutions. Its core product, the Templafy platform, connects and manages an organization's entire document ecosystem. Key features include template and content accessibility, dynamic personalization, document automation, brand and content validation, template governance, and PowerPoint productivity services. Templafy serves a wide range of industries, including banking, consulting, education, insurance, and legal, with a global presence across North America, Europe, Asia, and Australia. The company's innovative platform automates business document creation, ensuring brand compliance, governance, and improved productivity. It supports over 800 enterprise customers worldwide, such as KPMG and IKEA, and has raised $200 million in funding from prominent investors.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Templafy ApS, established in 2013, specializes in template and document management solutions. Its core product, the Templafy platform, connects and manages an organization's entire document ecosystem. Key features include template and content accessibility, dynamic personalization, document automation, brand and content validation, template governance, and PowerPoint productivity services. Templafy serves a wide range of industries, including banking, consulting, education, insurance, and legal, with a global presence across North America, Europe, Asia, and Australia. The company's innovative platform automates business document creation, ensuring brand compliance, governance, and improved productivity. It supports over 800 enterprise customers worldwide, such as KPMG and IKEA, and has raised $200 million in funding from prominent investors.

Mofibo, founded in Copenhagen in 2013, operates as one of the pioneering book subscription services globally. The company provides access to e-books through a proprietary platform, allowing consumers to enjoy a wide selection of titles for a monthly subscription fee. Currently available in three countries, Mofibo aims to expand its reach into additional markets within the next year. The company focuses on transforming the reading experience by employing a data-driven and customer-centric approach, seeking to enhance how millions of people engage with books.

Nuevolution is a small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a patented hybrid technology that combines wet chemistry and molecular biology to accelerate drug discovery. This platform facilitates the rapid synthesis and DNA-tagging of over 1 billion diverse small molecule compounds, allowing for efficient screening and identification of potent drug leads. Nuevolution partners with pharmaceutical and biotechnology companies, having established agreements with major firms such as Merck, GlaxoSmithKline, and Novartis. The company is also involved in a joint venture with EpiTherapeutics and ExpreS2ion Biotechnologies to develop small molecule drugs targeting epigenetic factors, supported by a project budget from the Danish High Technology Fund. Nuevolution focuses on developing treatments for oncology and inflammatory diseases and also provides contract research services, generating revenue from multiple countries, including Denmark, Sweden, and the USA. The company is privately owned by several key Scandinavian investors.

Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011 and based in Copenhagen. The company specializes in the development and commercialization of antibiotics aimed at treating multi-drug resistant bacterial infections, particularly those acquired in hospital settings. Its primary focus includes complicated urinary tract infections and hospital or ventilator-acquired pneumonia, which are often caused by resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Adenium Biotech's lead product, Arenicin, is a non-hemolytic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against Gram-negative pathogens. The company operates as a semi-virtual biotech entity, supported by a team of experts and an international scientific advisory board, with the goal of advancing the Arenicin program through clinical development and regulatory filing.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.